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Abstract
Background
The serum biomarker cancer antigen 125 (CA125) is widely used as an investigation for
possible ovarian cancer in symptomatic women presenting to primary care. However, its
diagnostic performance in this setting is unknown. We evaluated the performance of CA125
in primary care for the detection of ovarian and non-ovarian cancers.
Methods and findings
We studied women in the United Kingdom Clinical Practice Research Datalink with a CA125
test performed between 1 May 2011–31 December 2014. Ovarian and non-ovarian cancers
diagnosed in the year following CA125 testing were identified from the cancer registry.
Women were categorized by age: <50 years and�50 years. Conventional measures of test
diagnostic accuracy, including sensitivity, specificity, and positive predictive value, were cal-
culated for the standard CA125 cut-off (�35 U/ml). The probability of a woman having can-
cer at each CA125 level between 1–1,000 U/ml was estimated using logistic regression.
Cancer probability was also estimated on the basis of CA125 level and age in years using
logistic regression. We identified CA125 levels equating to a 3% estimated cancer probabil-
ity: the “risk threshold” at which the UK National Institute for Health and Care Excellence
advocates urgent specialist cancer investigation.
A total of 50,780 women underwent CA125 testing; 456 (0.9%) were diagnosed with
ovarian cancer and 1,321 (2.6%) with non-ovarian cancer. Of women with a CA125 level
�35 U/ml, 3.4% aged <50 years and 15.2% aged�50 years had ovarian cancer. Of women
with a CA125 level�35 U/ml who were aged�50 years and who did not have ovarian can-
cer, 20.4% were diagnosed with a non-ovarian cancer. A CA125 value of 53 U/ml equated
to a 3% probability of ovarian cancer overall. This varied by age, with a value of 104 U/ml in
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All data used in this study are available from CPRD
40-year-old women and 32 U/ml in 70-year-old women equating to a 3% probability. The
main limitations of our study were that we were unable to determine why CA125 tests were
performed and that our findings are based solely on UK primary care data, so caution is
need in extrapolating them to other healthcare settings.
Conclusions
CA125 is a useful test for ovarian cancer detection in primary care, particularly in women
�50 years old. Clinicians should also consider non-ovarian cancers in women with high
CA125 levels, especially if ovarian cancer has been excluded, in order to prevent diagnostic
delay. Our results enable clinicians and patients to determine the estimated probability of
ovarian cancer and all cancers at any CA125 level and age, which can be used to guide indi-
vidual decisions on the need for further investigation or referral.
Author summary
Why was this study done?
• CA125 is widely used as a test for ovarian cancer in women presenting with relevant
symptoms, both in the UK and internationally.
• CA125 has been extensively evaluated in the specialist care setting and in screening
studies but little was known about its diagnostic performance in primary care, where
most patients with ovarian cancer first present.
What did the researchers do and find?
• We evaluated the diagnostic performance of CA125 in 50,780 women undergoing test-
ing in English general practice.
• Of women with CA125 levels above the current abnormal cut-off, 10.1% were diagnosed
with ovarian cancer and a further 12.3% with another form of cancer.
• Cancer was more common in women with abnormal CA125 levels if they were�50
years of age.
• We developed models to estimate the probability of ovarian cancer and all cancer based
on a woman’s age and CA125 level.
What do these findings mean?
• Clinicians should consider the possibility of non-ovarian cancer, in addition to ovarian
cancer, in women with high CA125 levels.
• Our models will enable patients and clinicians to determine the estimated probability of
cancer based on an individual’s age and CA125 level.
• This information can be used to help make decisions about the need for further investi-
gation or urgent referral to a specialist.
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Scores.
• The findings should also help inform guidelines, as they will allow recommendations
for further testing to be made on the basis cancer probability rather than a single CA125
cutoff.
Introduction
Ovarian cancer is the eighth most common cancer to affect women worldwide, accounting for
over 384,000 deaths in 2018 [1]. Survival depends on stage at diagnosis, with five-year net sur-
vivals of 93% for stage I, 68% for stage II, 27% for stage III, and 13.4% for stage IV disease [2].
Most women are diagnosed following a symptomatic presentation [3], and, in healthcare sys-
tems in which general practitioners (GPs) play a gatekeeping role, this initial presentation usu-
ally takes place in primary care [4].
Symptoms can occur at all stages of ovarian cancer [5]. However, they are usually nonspe-
cific and are common in women without ovarian cancer, so they only have modest positive
predictive values for the disease [5,6]. The serum biomarker cancer antigen 125 (CA125) is
widely used in countries around the world, including the United States, Australia, Canada, and
Ireland, as an investigation for ovarian cancer in symptomatic women presenting to primary
care [7]. In 2011, the United Kingdom National Institute for Health and Care Excellence
(NICE) recommended that women with symptoms of possible ovarian cancer be tested for
CA125 in primary care, with further investigation advocated in those with CA125 levels�35
U/ml [8]. The chosen cutoff of 35 U/ml is the conventional upper limit of normal for CA125
and derives from a study in which 1% of healthy women and 82% of patients with ovarian can-
cer had a CA125 level>35 U/ml [9].
CA125 has been studied extensively in screening studies and in women in secondary care
with pelvic masses but not in women presenting with symptoms of possible ovarian cancer in
primary care. The NICE recommendations on CA125 testing for symptomatic women are
based on extrapolated secondary care and screening data rather than primary care data [8].
The performance characteristics of a test vary with disease prevalence, disease severity, and the
prevalence of other conditions that elevate test levels, so it is important to evaluate CA125
within the intended population [10].
When evaluating the diagnostic performance of a test such as CA125, it is standard practice
to report accuracy characteristics, including the positive predictive value (PPV), after applying
a particular cutoff. However, the PPV provides the “average” probability of disease for all
women with a test level at or above the set cutoff rather than the probability of disease at a
given test level. Knowledge of the probability of cancer at any given CA125 level is likely to be
more clinically useful than the PPV, as it would allow patients and clinicians to interpret their
individual CA125 test results, which could help guide decisions on the need for further investi-
gations. NICE revised their cancer guidance in 2015, using a “risk threshold” of�3% as the
threshold for urgent cancer investigation in symptomatic women, but ovarian cancer guid-
ance, including the chosen CA125 cut-off of 35 U/ml, remained unchanged [11]. Knowledge
of the estimated probability of cancer at each CA125 level could help inform health policy both
in the UK and internationally.
The primary aim of this study was to explore the relationship between CA125 level and
ovarian cancer probability, to identify the CA125 level at which a 3% probability of ovarian
cancer was reached. Given the nonspecific nature of ovarian cancer symptoms, and reports
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indicating CA125 is commonly elevated in other cancers [12,13], a second aim was to explore
the relationship between CA125 level and the probability of all cancers. To allow comparison
with existing literature on CA125 diagnostic accuracy, we also calculated conventional test per-
formance characteristics, including PPV, sensitivity, and specificity, applying the standard cut-
off (�35U/ml).
Methods
Ethics statement
The study was approved by the Independent Scientific Advisory Committee (ISAC) for the
Medicines and Healthcare Products Regulatory Agency (protocol number 18_184). All data
were provided to researchers in an anonymized form, and individual consent was not
required.
Data source
This was a retrospective cohort study using linked data from the Clinical Practice Research
Datalink (CPRD) GOLD dataset and the National Cancer Registration and Analysis Service
(NCRAS). The CPRD GOLD dataset contains anonymized, coded, primary care data includ-
ing demographics, laboratory results, symptoms, and diagnoses for around 11 million
patients. It is broadly representative of the UK population [14]. The NCRAS (English cancer
registry) collects cancer registration data on patients, including detailed information on
tumor topography, stage, and date of diagnosis. NCRAS obtains data from multiple sources
including hospitals, GP surgeries, and death certificates and reports a near 100% case ascer-
tainment [15]. Linkage of CPRD and NCRAS data was performed at a patient level by a
third party, National Health Service (NHS) Digital [16]. As NCRAS only collects details of
cancers diagnosed in England, the study was restricted to English general practices. The
approved ISAC protocol, which covers several linked studies, is included in the S1 Text and
S2 Text.
This report conforms to the STARD and RECORD statements [17,18]. A completed
STARD checklist is included with this article (S3 Text).
Participants
We included women with a code for CA125 measurement in primary care (S1 Table) between
1 May 2011 and the 31 December 2014. There has never been a national ovarian cancer screen-
ing program in the UK, and the only indication for CA125 testing in English primary care is a
presentation with a symptom of possible ovarian cancer. As such, we assumed that CA125-
tested women were symptomatic.
Women who were<18 years old or registered at a GP practice not deemed “up-to-stan-
dard” on data quality by CPRD on the date of their first CA125 test during this period were
excluded [14]. Women with a record of ovarian cancer in NCRAS data on or before the
CA125 test date were also excluded, as were women with a CA125 test in the 12 months before
the first CA125 test during the study period. Only CA125 entries recorded in standard equiva-
lent units of CA125 measurement (U/ml, IU/ml, KU/L, KIU/L) were accepted. Although
NICE recommends a CA125 cutoff of�35 U/ml, individual laboratory cutoffs varied. We
excluded CA125 values associated with spurious laboratory cutoffs (245, 420, and 455 U/ml)
and those where no cutoff was given. Subsequent sensitivity analyses, including CA125 entries
recorded in all units and associated with all laboratory upper cutoffs, had minimal impact on
our results. The first CA125 test during the study period was used in analyses.
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Clinical outcomes
Primary outcome. Our primary clinical outcome was the diagnosis of ovarian cancer, as
recorded using International Classification of Diseases (ICD)-10 codes in NCRAS data, in the
12 months following the initial CA125 test. With reference to the International Federation of
Gynaecology and Obstetrics (FIGO) and WHO classifications [19,20], we defined ovarian can-
cer as an ovarian malignancy (C56), a fallopian tube malignancy (C57.0), a peritoneal malig-
nancy (C48.1, C48.2), or a neoplasm of uncertain behavior of the ovary (D39.1). We assumed
that cancer diagnosed within 12 months of the initial CA125 test was present at the time of
testing. It is possible that incidental ovarian cancers may arise and be diagnosed in the year fol-
lowing testing or that it may take longer than 1 year from presentation in primary care to diag-
nosis. A period of 1 year, which has been used widely in similar studies [21,22], was chosen as
a compromise between minimizing the inclusion of incidental cancers and maximizing the
inclusion of relevant cancers.
Our primary outcome included borderline ovarian tumors, as these are treated collectively
with invasive tumors in NICE recommendations on CA125 testing and generally require sur-
gical management [23]. Although their timely detection in symptomatic women is important,
borderline tumors are less likely to cause an elevation in serum CA125, and their prognosis is
very good even if detected late [23]. We therefore performed a subanalysis in which invasive
ovarian cancer formed the outcome.
Secondary outcome. Our secondary outcome was the diagnosis of non-ovarian cancers.
The earliest record of cancer, excluding nonmelanoma skin cancers, was identified in the 12
months following initial CA125 testing in women without ovarian cancer. We refer to this
group of cancers as “non-ovarian cancer.” Where we discuss the combined non-ovarian and
ovarian cancer groups, we use the term “all cancers.”
Descriptive outcomes. In order to report the symptoms that may have triggered CA125
testing, symptoms coded in the 30 days before CA125 testing were identified from CPRD data
using a code list of ovarian cancer symptoms from current NICE guidelines [11].
Ovarian cancer stage was determined using the Tumor Nodes Metastasis (TNM) staging
system or, where not recorded, the FIGO staging system, and the proportions of ovarian can-
cers at each stage identified [19].
The histology of invasive ovarian tumors was identified from NCRAS data and categorized
on the basis of ICD10 codes.
Statistical analysis
We calculated the PPV, negative predictive value (NPV), sensitivity, and specificity of CA125
for ovarian cancer at or above the current cut-off (35 U/ml). A nonparametric receiver opera-
tor characteristic (ROC) curve was constructed, and the area under the curve (AUC) deter-
mined. This analysis was repeated for invasive ovarian cancer and all cancers combined. After
excluding ovarian cancer patients, it was also repeated for non-ovarian cancer. As ovarian can-
cer incidence is greater in older women and most cases occur in women post-menopause, we
repeated all analyses for women <50 years and�50 years of age [24].
We used logistic regression to examine the relationship between CA125, as a continuous
variable, and ovarian cancer diagnosis. CA125 level was highly skewed, and so it was log-trans-
formed prior to regression analysis. Log CA125 was centered on a value of 3, the closest integer
to the mean. The relationship between log CA125 level and ovarian cancer was nonlinear. To
account for this, we used restricted cubic splines. As recommended by Harrell [25], we com-
pared the Akaike Information Criterion (AIC) for models containing 3, 4, and 5 knots. The
5-knot model produced the smallest AIC and so was taken forward. Knots were placed at
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standard, equally spaced percentiles of the marginal distribution of the variable (S4 Text) [25].
This regression model was used to predict the odds of cancer for a range of CA125 levels (1–
1,000 U/ml), which were then converted into probabilities.
The logistic regression analysis was repeated for the<50 years and�50 years age groups.
Significant differences were noted between these groups in terms of the estimated ovarian can-
cer probabilities. Given this, and on the recommendation of a peer reviewer, we constructed a
multivariable regression model including age in years (mean centered) as a continuous vari-
able and CA125 level, applying the same approach as described here previously. Five knots
were included for each variable (S4 Text). This regression model was used to predict the odds
of ovarian cancer for CA125 levels (1–1,000 U/ml) in women of different ages. Results for
women aged 30, 40, 50, 60, 70, and 80 years of age are presented as examples in this paper.
All the aforementioned steps were repeated for our secondary outcome and for the invasive
cancer subanalysis. Full details of all models are included in S4 Text.
Statistical software. All analyses were performed in Stata version 15.1 (StataCorp, www.
stata.com). The DIAGT module was used to calculate summary diagnostic accuracy statistics
[26]. All confidence intervals (CI) are reported at the 95% level.
Results
After exclusions, our cohort consisted of 50,780 women (Fig 1).
The ovarian cancer incidence in the cohort was 0.9% and was 3 times higher in the�50
years group than the<50 years group (Table 1). The median interval between CA125 testing
and ovarian cancer diagnosis was 42 days (interquartile range: 25–62 days) and the mean
patient age was 56 years (range: 18–102 years).
Cancer stage
Of the 456 ovarian cancers, 172 (37.7%) were stage I or II, and 209 (45.8%) were stage III or
IV. No stage was recorded in 75 (16.4%) cases (S2 Table).
Cancer morphology and histology
Of the ovarian cancers diagnosed, 21.5% (n = 98) were borderline tumors. The proportion of
malignancies that were borderline varied with age, with 50% of tumors in the<50 years group
and 15.4% in the�50 years group being borderline (S3 Table). Serous epithelial tumors were
the most common tumor type, accounting for 48.6% (n = 174) of invasive tumors. In the<50
years group, 12.5% (n = 5) of invasive tumors were of nonepithelial origin compared with
2.5% (n = 8) in the�50 years group.
Recorded symptoms
Symptoms of possible ovarian cancer were recorded for 24,269 women (47.8%) on the same
day or in the 30 days preceding CA125 testing; the most common was abdominal pain
(Table 2). Multiple symptoms were recorded in 1,477 (6.1%) women.
Diagnostic performance applying the standard cutoff (�35 U/ml)
The diagnostic performance characteristics of CA125 were calculated after applying the stan-
dard cutoff (�35 U/ml) (Table 3). At or above the 35 U/ml cutoff, CA125 demonstrated a
PPV of 10.1% (95% CI 9.1–11.2), an NPV of 99.8% (95% CI 99.7–99.8), a sensitivity of 77.0%
(95% CI 72.8–80.8%) and a specificity of 93.8% (95% CI 93.6–94.0) for ovarian cancer. The
AUC was 0.92 (95% CI 0.90–0.93). The AUC was greater in the�50 years group (AUC: 0.93,
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95% CI 0.92–0.95) than the <50 years group (AUC 0.86, 95% CI 0.82–0.91) and the PPV, sen-
sitivity and specificity were also higher in the�50 group.
When the outcome was restricted to invasive ovarian cancers, CA125 demonstrated a
slightly lower PPV (8.8%, 95% CI 7.8–9.8), and a higher sensitivity (84.9%, 95% CI 80.8–88.5)
(Table 3).
Of the 50,324 women without ovarian cancer, 1,321 (2.6%) were diagnosed with a non-
ovarian cancer. The incidence of non-ovarian cancers in women with a CA125 <35 U/ml was
Table 1. Patient numbers, incidence of raised CA125 tests (�35 U/ml) and cancer incidence by age group.
<50 years �50 years Overall cohort
Number of patients, N 19,694 31,086 50,780
Raised (�35 U/ml) CA125, N (%) 1,482
(7.5)
1,986
(6.4)
3,468
(6.8)
Ovarian cancers, N (%) 80
(0.4)
376
(1.2)
456
(0.9)
Non-ovarian cancer, N (%) 161
(0.8)
1,160
(3.7)
1,321
(2.6)
CA125, cancer antigen 125.
https://doi.org/10.1371/journal.pmed.1003295.t001
Fig 1. Flow diagram illustrating the identification of the study cohort and application of exclusion criteria. UTS is a quality metric, provided by CPRD,
which indicates if the data from a GP practice are of sufficient quality to be used in research [14]. CA125, cancer antigen 125; CPRD, Clinical Practice Research
Datalink; NCRAS, National Cancer Registration and Analysis Service; UTS, up to standard.
https://doi.org/10.1371/journal.pmed.1003295.g001
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Table 2. Ovarian cancer symptoms and signs coded in the 30 days prior to CA125 testing.
Symptom/sign Patients, N (%)
Abdominal pain 11,933 (49.2)
Abdominal distension or bloating 5,686 (23.4)
Change in bowel habit 2,866 (11.8)
Fatigue 1,692 (7.0)
Pelvic pain 1,632 (6.7)
Weight loss 913 (3.8)
Urinary frequency 552 (2.3)
Abdominal or pelvic mass 419 (1.7)
Loss of appetite 113 (0.5)
Urinary urgency 86 (0.4)
Ascites 26 (0.1)
% is the proportion of patients with a given symptom out of the total number of patients who have a coded symptom
(N = 24,269). Categories are not mutually exclusive: a patient may have had more than 1 symptom coded.
CA125, cancer antigen 125.
https://doi.org/10.1371/journal.pmed.1003295.t002
Table 3. Performance characteristics of CA125 for ovarian cancer, invasive ovarian cancer, non-ovarian cancers and all cancers.
Cancer Group PPV, %
(95% CI)
NPV, %
(95% CI)
Sensitivity, % (95% CI) Specificity, % (95% CI) AUC
(95% CI)
Ovarian All ages 10.1
(9.1–11.2)
99.8
(99.7–99.8)
77.0
(72.8–80.8)
93.8
(93.6–94.0)
0.92
(0.90–0.93)
<50 years 3.4
(2.5–4.4)
99.8
(99.8–99.9)
62.5
(51.0–73.1)
92.7
(92.3–93.1)
0.86
(0.82–0.91)
�50 years 15.2
(13.6–16.8)
99.7
(99.7–99.8)
80.1
(75.7–84.0)
94.5
(94.3–94.8)
0.93
(0.92–0.95)
Ovarian: invasive All ages 8.8
(7.8–9.8)
99.9
(99.9–99.9)
84.9
(80.8–88.5)
93.7
(93.5–93.9)
0.94
(0.92–0.96)
<50 years 2.0
(1.3–2.8)
99.9
(99.9–100)
72.5
(56.1–85.4)
92.6
(92.2–93.0)
0.88
(0.82–0.95)
�50 years 13.8
(12.4–15.4)
99.9
(99.8–99.9)
86.5
(82.2–90.0)
94.4
(94.2–94.7)
0.95
(0.93–0.97)
Non-ovarian All ages 12.3
(11.2–13.5)
98.0
(97.9–98.1)
29.1
(26.6–31.6)
94.4
(94.2–94.6)
0.68
(0.66–0.69)
<50 years 2.8
(2.0–3.8)
99.3
(99.2–99.4)
24.8
(18.4–32.3)
92.8
(92.5–93.2)
0.62
(0.58–0.67)
�50 years 20.4
(18.5–22.4)
97.2
(97.0–97.4)
29.7
(27.0–32.4)
95.5
(95.2–95.7)
0.70
(0.69–0.72)
All cancers All ages 21.2
(19.8–22.6)
97.8
(97.7–97.9)
41.4
(39.1–43.7)
94.4
(94.2–94.6)
0.74
(0.73–0.75)
<50 years 6.1
(4.9–7.4)
99.2
(99.0–99.3)
37.3
(31.2–43.8)
92.8
(92.5–93.2)
0.70
(0.67–0.74)
�50 years 32.5
(30.4–34.6)
96.9
(96.7–97.1)
42.0
(39.5–44.5)
95.5
(95.2–95.7)
0.76
(0.75–0.78)
PPV, NPV, sensitivity and specificity are calculated for a cutoff of �35 U/ml. Accuracy characteristics for “non-ovarian” cancer were calculated following exclusion of
patients with ovarian cancer.
AUC, area under the curve; CA125, cancer antigen 125; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.
https://doi.org/10.1371/journal.pmed.1003295.t003
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2.0%, whereas the incidence in women with a CA125�35 U/ml, which equates to the PPV for
non-ovarian cancers, was 12.3% (95% CI 11.2–13.5) (Table 3). This varied markedly between
the<50 years group (PPV 2.8%, 95% CI 2.0–3.8) and�50 years group (PPV 20.4%, 95% CI
18.5–22.4). The PPV for all cancers was 21.2% (95% CI 19.8–22.6). Almost half of patients
diagnosed with pancreatic and lung cancer in our cohort had CA125 levels�35 U/ml
(Table 4).
The probability of cancer by CA125 level
Fig 2 shows the relationship between CA125 level and the estimated probability of can-
cer, derived from logistic regression analyses. A CA125 level of 53 U/ml equated to a
probability of 3% (95% CI 2.6–3.5) for ovarian cancer, whereas a CA125 level of 18 U/ml
equated to a probability of 3% (95% CI 2.8–3.2) for all cancer. In a subanalysis in which
invasive ovarian cancer formed the outcome, a CA125 level of 68 U/ml equated to a 3%
probability.
Repeating the analysis in the <50 years and�50 years groups revealed that a much higher
CA125 level was required to reach the 3% probability for ovarian cancer in the<50 years
group (89 U/ml) than�50 years group (39 U/ml) (S4 Fig).
Table 4. Cancers diagnosed in women without ovarian cancer.
Cancer type
(ICD10 codes)
N N < 35 U/ml
(%)
N � 35 U/ml
(%)
Unknown primary
(C80)
46 8
(17)
38
(83)
Secondary: respiratory and digestive
(C78)
23 9
(39)
14
(61)
Pancreas
(C25)
93 47
(51)
46
(49)
Lung
(C34)
104 55
(53)
49
(47)
Liver, biliary
(C22, C23, C24)
34 21
(62)
13
(38)
Uterus
(C54, C55, D39.0)
132 84
(64)
48
(36)
Upper GI
(C15, C16, C17, D37.1, D37.2)
66 46
(70)
20
(30)
Lower GI
(C18, C19, C20, C21,D37.3,D37.4,D37.5)
255 197
(77)
58
(23)
Hematological
(C81, C82, C83, C84, C85, C90, C91, C92, C96, D45, D46, D47)
112 83
(74)
29
(26)
Kidneys, urinary tract
(C64, C65, C66, C67, D41)
78 65
(83)
13
(17)
Breast
(C50)
154 142
(92)
12
(8)
Other 224 180
(80)
44
(20)
Total 1,321 937
(71)
384
(29)
“Other” consists of cancers with fewer than 10 cases with CA125 values�35 U/ml. The cancers included in this
group and their frequencies are shown in S4 Table.
CA125, cancer antigen 125; ICD-10, International Classification of Diseases, 10th revision.
https://doi.org/10.1371/journal.pmed.1003295.t004
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The probability of ovarian cancer by age and CA125 level
Fig 3 illustrates the relationship between CA125 level and the estimated probability of ovarian
cancer at specific ages, derived from a logistic regression analysis. The probability of ovarian
cancer at a given CA125 level varied markedly by age. The CA125 level required to reach the
3% ovarian cancer probability threshold fell from 104 U/ml in 40-year-old women to 32 U/ml
in 70-year-old women. Similar age trends were noted when the analysis was repeated for inva-
sive ovarian cancer (S5 Fig) and all cancer (S6 Fig).
Discussion
In this cohort study of over 50,000 women who underwent CA125 testing in English general
practice, 10.1% of those with a CA125 at or above the conventional cutoff (35 U/ml) were
Fig 2. Relationship between CA125 level and estimated probability of ovarian cancer, invasive ovarian cancer, and all cancers. Estimated probabilities up to 8%
are shown for ovarian cancer, invasive ovarian cancer, and all cancers. CA125 levels that correspond to the closest integer probabilities of 3% are indicated. The
probabilities, which equate to a CA125 level of 35 U/ml, are also marked. Confidence intervals (95%) are displayed. Graphs showing probabilities at an extended
range of CA125 values (up to 500 U/ml) for ovarian cancer, invasive ovarian cancer, and all cancer are included in S1 Fig, S2 Fig, and S3 Fig, respectively. Data used
to construct these graphs (up to a CA125 level of 1,000 U/ml) are available via the University of Cambridge Repository [27]. CA125, cancer antigen 125; CI,
confidence interval.
https://doi.org/10.1371/journal.pmed.1003295.g002
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diagnosed with ovarian cancer, and 12.3% were diagnosed with a different cancer. Almost a
third of women aged�50 years with a CA125�35 U/ml were diagnosed with some form of
cancer. A CA125 level of 53 U/ml equated to an overall ovarian cancer probability of 3%—the
threshold at which the UK NICE advocates urgent investigation or referral in symptomatic
women. Marked variation was noted between women of different ages, with the 3% probability
reached at lower CA125 levels in 70-year-old women than younger or older women.
Study limitations
This study relied on coded routinely collected data, so it was not possible to determine exactly
why CA125 tests were requested. However, the only indication for CA125 testing in UK pri-
mary care is to investigate symptoms of possible ovarian cancer. We identified symptoms
recorded before CA125 testing, which may have been the trigger for testing. In contrast to
CA125 results, which are automatically transferred into the GP system from laboratories,
symptoms are not always coded but instead are often recorded in the free text within the GP
record, which cannot be accessed for research purposes [28]. We did not restrict our analysis
to women with a coded ovarian cancer symptom as this could introduce bias, given that symp-
toms are more likely to be coded if they are severe or persistent [28].
Fig 3. Relationship between CA125 level and estimated probability of ovarian cancer for women of different ages. Estimated ovarian cancer
probabilities are shown in relation to CA125 level for women of 30, 40, 50, 60, 70, and 80 years of age. CA125 levels that correspond to the closest integer
probabilities of 3% are indicated in red. Confidence intervals (95%) are displayed. Data used to construct these graphs (up to a CA125 level of 1,000 U/ml)
are available via the University of Cambridge Repository [27]. CA125, cancer antigen 125.
https://doi.org/10.1371/journal.pmed.1003295.g003
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Our results reflect real-world use of CA125 in English general practice. How CA125 is used
in primary care in other countries may differ from practice in England. Baseline CA125 levels
may also be affected by population characteristics, such as ethnicity, smoking status, and past
medical history [29]. We did not include these variables in our analysis as our aim was to
develop simple models that allow the estimated probability of cancer to be reported alongside
the CA125 result in general practice, without the need to collect further detailed information
from the patient. Although this study has significant international relevance, caution is needed
when translating our findings to other countries and healthcare systems.
We report ovarian cancer stage at diagnosis, but CA125 diagnostic accuracy was not ana-
lyzed by stage. As CA125 tests were performed at variable intervals in the 12 months preceding
diagnosis, such an analysis is likely to be misleading as an unknown number of cancers will
have progressed during that period.
We have employed restricted cubic splines to model the nonlinear nature of the relation-
ship between both age and CA125 level and cancer diagnoses. Although these provide a flexi-
ble approach to parameterizing the fitted relationships, there is a large degree of uncertainty at
the extremes of age and CA125 level, and so the cancer probabilities for very old and young
women and those with very low CA125 levels should be treated with caution, and the large CI
noted.
Results in the context of other studies
In their 2011 ovarian cancer guidelines, NICE estimated that 0.81% of symptomatic primary
care women with a CA125�35 U/ml would have ovarian cancer [8]. Economic modeling and
the recommendation for sequential testing with CA125 followed by ultrasound if the CA125
were abnormal was predicated on this estimate. Our findings indicate that the PPV is more
than 12 times higher than estimated. This is consistent with the only other UK report of the
PPV of CA125 in primary care, which found that 16 out of 152 women (11%) with a raised
CA125 level had ovarian cancer [13]. The sensitivity of CA125 for ovarian cancer in our study
was slightly lower—and the specificity higher—than reported in studies in which testing was
performed in women with a pelvic mass prior to surgery in secondary care [30]. This is to be
expected as tests generally have lower sensitivity and higher specificity in populations with a
lower disease prevalence—the spectrum effect [10]. As anticipated, the PPVs for ovarian can-
cer in our cohort were lower than in secondary care patients with pelvic masses [31] and
higher than in asymptomatic screening populations [32].
One of the most striking findings in our study was the high incidence of non-ovarian can-
cers in those with elevated CA125 levels, particularly in women aged 50 years or older. This
reflects the nonspecific nature of ovarian cancer symptoms and also that CA125 is frequently
raised in women with a variety of non-ovarian malignancies [12]. Crawford and colleagues
reported that 16 out of 152 women (11%) referred from primary care with a raised CA125
were diagnosed with a non-ovarian cancer [13]. Furthermore, in asymptomatic screening pop-
ulations, a higher incidence of non-ovarian cancers has been noted in women with raised
CA125 levels (6.9%) than with normal CA125 levels (1.6%) [33].
We found that the estimated probability of ovarian cancer for a given CA125 level rose
with age to peak in women in their seventies, which mirrors UK age-specific cancer inci-
dence rates [34]. The exception was very young women—the probability of ovarian cancer at
a given CA125 level was higher in women aged 30 than aged 40. This probably reflects GP
testing practices in very young women (in whom ovarian cancer is extremely rare), with GPs
having a strong reason to request a CA125 test in these women, thereby raising the pretest
probability.
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Clinical interpretation of the findings
Of the CA125 tests performed, 39% were in women <50 years of age; however, ovarian cancer
is predominantly a disease of older and postmenopausal women. This is reflected in our find-
ings, as only 18% of ovarian cancers and 11% of the invasive subtype occurred in women
under 50. All measures of test performance, save for the NPV, were worse in women under 50
years than 50 years and over, even when borderline malignancies (which were more common
in the younger age group) were excluded. A greater proportion of invasive tumors in the<50
years group were mucinous epithelial and nonepithelial cancers, both of which have less pro-
pensity to elevate serum CA125 than other ovarian cancer types, likely contributing to poorer
test performance in the younger age group [31]. The results of our regression analysis indicate
that, overall, only 1 in 110 women<50 years with a CA125 of exactly 35 U/ml will have an
ovarian cancer, and only 1 in 308 will have an invasive subtype. Investigating younger women
for ovarian cancer when there is high suspicion is important, but given the low incidence of
ovarian cancer and relatively poor test performance in women under 50 years, CA125 tests
should be performed and interpreted with caution in this group.
The total number of non-ovarian cancers diagnosed in women with raised CA125 levels
exceeded that of ovarian cancers, but the numbers of women with each type of non-ovarian
cancer was small. In isolation, CA125 is unlikely to be a useful test for the detection of individ-
ual types of non-ovarian cancer in primary care, most of which have superior triage tests.
However, given our study findings, a high CA125 level in a woman�50 years should raise a
suspicion of non-ovarian cancer. Clinicians should consider these cancers and whether further
investigation is required, particularly if ovarian cancer has been excluded. Research is needed
to determine the most appropriate follow-up and testing strategy for these women in order to
ensure prompt diagnosis.
When assessing test performance, it is standard practice to evaluate test characteristics
using a cutoff, above which the test is deemed abnormal and below which it is deemed normal.
As per convention, we have presented this for CA125, applying the standard�35 U/ml cutoff.
However, where the probability of having a disease varies markedly with the test level, PPV is
of limited value in informing decisions about individual patients, as it effectively provides an
average probability of disease for all women with “abnormal” results. In this study, women
with very high CA125 values had a very high probability of being diagnosed with cancer. Con-
versely, those with CA125 levels around the 35 U/ml cutoff had a much lower probability of
being diagnosed with cancer than the PPV would appear to indicate. In this study, we have
quantified the risk of cancer in individuals with specific CA125 values at specific ages. This
should be of much more use clinically than PPVs.
Estimated cancer probabilities will allow women and clinicians to interpret their individual
CA125 result and could inform health policy both in the UK and internationally. For example,
NICE currently recommend that women with a CA125�35 U/ml, whether 35 U/ml or 1,000
U/ml, should be referred for an ultrasound scan, whereas no further investigations for ovarian
cancer are advocated in women with levels below the cutoff. Instead, our results could be used
to triage women of different ages, selecting those with a high probability of ovarian cancer for
expedited referral and investigation. Women with a probability in excess of the NICE risk
threshold of 3% could be referred via the urgent cancer pathway for specialist gynecology
assessment and/or imaging. Women with lower probabilities might, after discussion between
clinician and patient, be investigated using routine ultrasound, recognizing the fact that
patients would opt for cancer testing at risk levels as low as 1% [35]. As only a woman’s age
and CA125 level are required to determine the cancer probability from our results, this infor-
mation could readily be incorporated into laboratory information technology (IT) systems,
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reported alongside the CA125 level, and communicated to patients in clear terms, e.g., “1 in 30
women of your age who have the same CA125 level in general practice will have ovarian
cancer.”
Although we have focused on the UK NICE 3% probability threshold for urgent cancer
referral, our results would also allow alternative thresholds for referral to be implemented. A
lower probability threshold may lead to the detection of more cancers, but this would come at
the cost of larger numbers of cancer-free women being referred and further investigated,
which can have negative consequences such as increased patient anxiety and financial cost
[36]. Conversely, employing a higher probability threshold would lead to fewer cancer-free
women being referred unnecessarily, but more cancers may be missed. A full health economic
evaluation would greatly improve understanding of the implications of applying different
referral thresholds.
The Refining Ovarian Cancer Test Accuracy Scores (ROCkeTS) study, a large ongoing pro-
spective study in the UK evaluating a range of diagnostic tests and algorithms for ovarian can-
cer in secondary care, may provide insight into the most appropriate post-CA125 testing
strategy [37]. Any such strategy should take account of the high incidence of non-ovarian can-
cers in women with high CA125 levels, as pelvic ultrasound alone will miss many of these
malignancies. Other imaging modalities such as computed tomography (CT), which can detect
multiple CA125 elevating cancers including ovarian, lung, and pancreatic cancer [38–40] and
which is already used in several countries to investigate symptomatic women with elevated
CA125 levels [7], could be appropriate. Further research is also needed to determine whether
CA125 re-testing in primary care should be performed in women who have a normal ultra-
sound scan but persistent symptoms, as there is evidence from screening studies that a rising
CA125 is associated with a higher risk of ovarian cancer, even if ultrasound is normal [41].
Conclusions
CA125 is a useful test for detecting ovarian cancer in primary care, particularly in women aged
50 years and over. Given the high incidence of non-ovarian cancers in women with elevated
CA125 levels, clinicians should consider alternative cancers particularly when ovarian cancer
has been excluded. The results of this study will enable patients and clinicians to interpret their
CA125 result in terms of the probability of cancer at the pertinent CA125 level and age. The
findings will also allow policy makers to provide recommendations for post-CA125 investiga-
tions on the basis of the probability of undiagnosed cancer, which could enable the expedited
investigation and referral of those women most likely to have a cancer.
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